Mesoblast, a regenerative medicine company, has announced the results of a Phase 2 clinical trial for lumbar spinal fusions using the company's NeoFuse product. NeoFuse is comprised of allogeneic Mesenchymal Precursor Cells. The study covered 24 patients at fives sites who underwent surgical treatment for one or two level fusions using the posterior approach. After 12 months, 85.7 percent of the patients achieved fusion when given 25MPCs. Approximately 62 percent of the patients with 75MPC achieved fusion and 75 percent of the patients in the control group, who underwent the bone autograft standard of care, achieved fusion.
These results support the continuation of the trial into Phase 3 for interbody lumbar fusion, which Mesoblast will initiate later this year.
More Articles on Spine Surgery:
Optimize Cost Effective Online Spine Practice Marketing: Q&A With Dr. Bryan Oh of BASIC Spine
6 Spine Experts From Beth Israel Join Mount Sinai School of Medicine
Duke University Spine Center Moves Locations
These results support the continuation of the trial into Phase 3 for interbody lumbar fusion, which Mesoblast will initiate later this year.
More Articles on Spine Surgery:
Optimize Cost Effective Online Spine Practice Marketing: Q&A With Dr. Bryan Oh of BASIC Spine
6 Spine Experts From Beth Israel Join Mount Sinai School of Medicine
Duke University Spine Center Moves Locations